New drug for rare childhood disease; price tag, $702,000 a year
And an explosive statement from the FDA
by Jon Rappoport
The FDA has just approved a new drug, Brineura, for a rare childhood brain-disease known as CLN2, which progresses quickly and is considered fatal.
BioMarin, the drug’s manufacturer, has pegged the yearly price of the drug for a patient at an astronomical $702,000. Discounts will be offered—the average annual price for the patient will come down to $486,000.
While recovering from the pricing shock, consider this statement from the FDA: “Brineura is the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older…”
Translation: There is no claim that the drug cures the disease. The drug may slow down the progression of only one of the many symptoms. For $486,000 a year, if the patient lives for a year.
View original post 491 more words